NVUS - Novus Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8400
+0.0300 (+1.07%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.8100
Open2.8100
Bid2.83 x 800
Ask3.97 x 900
Day's Range2.8200 - 3.1500
52 Week Range2.5500 - 8.6100
Volume48,986
Avg. Volume35,477
Market Cap26.759M
Beta (3Y Monthly)0.02
PE Ratio (TTM)N/A
EPS (TTM)-1.37
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Business Wire10 days ago

    Novus Therapeutics Announces Formation of Scientific Advisory Board

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the formation of a new Scientific Advisory Board (SAB), which is comprised of international experts in otolaryngology, pediatrics, and infectious diseases. The SAB will work closely with the Novus management team to advance OP0201, the company’s lead product candidate being developed for otitis media. “We are honored to have such a highly distinguished team of experts join our newly formed scientific advisory board,” said Dr. Catherine Turkel, President of Novus Therapeutics.

  • Business Wire17 days ago

    Novus Therapeutics Doses First Subjects in Phase 1 Study of OP0201

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that it has dosed the first adult subjects in the low dose cohort of a phase 1 clinical trial of OP0201, the company’s lead product candidate being developed for otitis media. “The initiation of this phase 1 study represents a significant milestone for the company. Completion of this safety study will position us to quickly move forward and evaluate OP0201 in children with otitis media,” said Dr. Catherine Turkel, President of Novus Therapeutics.

  • Business Wire29 days ago

    Novus Therapeutics to Present at the 2018 Piper Jaffray Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference to be held November 27-29, 2018 at the Lotte New York Palace. Gregory J. Flesher, CEO of Novus Therapeutics, is scheduled to present a company overview at 12:50 pm EST on Wednesday, November 28, 2018. Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”).

  • Business Wirelast month

    Novus Therapeutics Reports Third Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended September 30, 2018.

  • Business Wire3 months ago

    Novus Therapeutics to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that Gregory J. Flesher, Chief Executive Officer of Novus, will present at the Ladenburg Thalmann 2018 Healthcare Conference in New York City on Tuesday, October 2, 2018 at 9:30 AM Eastern Time.

  • Business Wire3 months ago

    Novus Therapeutics to Postpone Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has elected to postpone the previously announced public offering of its common stock due to market conditions, including valuation sensitivity at the current share price. As of June 30, 2018, the company had $19.2 million in cash and cash equivalents. Novus believes that its current cash will be sufficient to achieve several key milestones in 2019, including completion of its planned phase 1 clinical trials with OP-02 in healthy adults, children with otitis media with effusion (“OME”), and adults with acute otitis media (“AOM”).

  • Business Wire3 months ago

    Novus Therapeutics Announces Proposed Public Offering of Common Stock

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”), today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. Novus expects to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 900,000 shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

  • Business Wire4 months ago

    Novus Therapeutics Reports Second Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended June 30, 2018.

  • Business Wire6 months ago

    Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis Media

    Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), announced receipt of final meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C meeting held at the Company’s request to discuss its OP-02 development program in otitis media. “The FDA provided guidance on our planned 505(b)(2) development path for OP-02 and confirmed that no additional preclinical or clinical studies beyond our planned phase 1 safety study in healthy adults will be required before initiation of phase 2 studies in children 6-months of age or older with otitis media,” said Dr. Catherine C. Turkel, President of Novus Therapeutics, Inc.

  • Business Wire7 months ago

    Novus Therapeutics Reports First Quarter 2018 Financial Results

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter ended March 31, 2018 and provided a corporate update.

  • Business Wire8 months ago

    Novus Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update

    Novus Therapeutics, Inc. , a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat , today announced financial results for the quarter and year ended December 31, 2017 and provided a corporate update.

  • Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?
    Simply Wall St.11 months ago

    Should You Invest In The Healthcare Stock Novus Therapeutics Inc (NASDAQ:NVUS)?

    Novus Therapeutics Inc (NASDAQ:NVUS), a USD$29.55M small-cap, operates in the healthcare industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasingRead More...